Age and gender influences on rate and duration of paroxysmal atrial fibrillation

Pacing Clin Electrophysiol. 1998 Nov;21(11 Pt 2):2455-8. doi: 10.1111/j.1540-8159.1998.tb01200.x.

Abstract

The influence of age and gender on the character of paroxysmal atrial fibrillation (PAD) has not been described.

Methods: The heart rate (HR) during PAF in patients receiving placebo or antiarrhythmic therapy was analyzed. Data from 177 24-hour Holter recordings were analyzed to mark the onset and termination of PAF and converted into RR interval files. PAF episodes lasting at least 2 minutes and containing < or = 20% noise were included. HR during the first 30-second segment versus during the remainder of the episode, and the duration of PAF episodes were compared among groups of different ages and sex (Wilcoxon test).

Results: 236 episodes from 55 recordings in 32 patients (all patients: 61.4 +/- 12.8 years; men (19): 58.5 +/- 12.6 years; women (13) 65.5 +/- 12.4 years, P = ns for difference in age) fulfilled the inclusion criteria. Women had a higher mean heart rate at AF onset (123 +/- 35 beats/min vs 115 +/- 20 beats/min, P = 0.02) and during the remainder of the episode (120 +/- 25 beats/min vs 112 +/- 22 beats/min at the start, P = 0.01, and 116 +/- 26 beats/min vs 108 +/- 18 beats/min subsequently, P = 0.01). Episodes tended to be longer in women (mean 89.8 min vs 50.5 min, P = NS) and in the aged (mean 83.8 min vs 46.9 min, P = NS).

Conclusion: PAF episodes are associated with faster heart rates and last longer in women, which may reflect differing autonomic responses to AF. A slower ventricular rate during PAF in older patients probably reflects an increasing prevalence of impaired atrioventricular conduction.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged
  • Anti-Arrhythmia Agents / therapeutic use
  • Atenolol / therapeutic use
  • Atrial Fibrillation / drug therapy
  • Atrial Fibrillation / epidemiology*
  • Atrial Fibrillation / physiopathology
  • Cross-Over Studies
  • Digoxin / therapeutic use
  • Disopyramide / therapeutic use
  • Double-Blind Method
  • Electrocardiography, Ambulatory*
  • Female
  • Heart Rate / physiology*
  • Humans
  • Male
  • Middle Aged
  • Sex Factors
  • Signal Processing, Computer-Assisted
  • Time Factors

Substances

  • Anti-Arrhythmia Agents
  • Atenolol
  • Digoxin
  • Disopyramide